Morace G, Amato G, Bistoni F, Fadda G, Marone P, Montagna M T, Oliveri S, Polonelli L, Rigoli R, Mancuso I, La Face S, Masucci L, Romano L, Napoli C, Tatò D, Buscema M G, Belli C M C, Piccirillo M M, Conti S, Covan S, Fanti F, Cavanna C, D'Alò F, Pitzurra L
Istituto di Microbiologia, Università degli Studi di Milano, Italy.
J Clin Microbiol. 2002 Aug;40(8):2953-8. doi: 10.1128/JCM.40.8.2953-2958.2002.
Fluconazole susceptibility among 800 clinical Candida isolates (60% C. albicans) and two control strains (C. krusei ATCC 6258 and C. parapsilosis ATCC 22019) was tested with the NCCLS M27-A method (gold standard) and six commercial products (Candifast, disk, Etest, Fungitest, Integral System Yeasts, and Sensititre YeastOne). Results were classified as susceptible, susceptible-dose dependent, or resistant using M27-A breakpoints or, for Fungitest, Integral System Yeasts, and Candifast, as susceptible, intermediate, or resistant, according to the manufacturers' instructions. Concordance with NCCLS M27-A results was analyzed with the chi(2) test. Intra- and interlaboratory reproducibility was also evaluated. NCCLS M27-A (90.1%), Etest (93.1%), Sensititre YeastOne (93.1%), disk (96.7%), Fungitest (92.6%), Integral System Yeasts (40.6%), and Candifast (6.0%) classified the indicated percentages of C. albicans isolates as susceptible. Among non-C. albicans strains, the percentages of susceptible isolates were as follows: NCCLS M27-A, 74.0%; Etest, 83.8%; Sensititre YeastOne, 64.1%; disk, 60.6%; Fungitest, 76.6%; Integral System Yeasts, 28.3%; and Candifast, 27.4%. All methods except Candifast and Integral System Yeasts showed good agreement with NCCLS M27-A results for both C albicans and non-C. albicans isolates. Intralaboratory reproducibility was excellent for NCCLS M27-A, Etest, Sensititre YeastOne, disk, and Fungitest (88 to 91%). Similar results emerged from the interlaboratory reproducibility evaluation. Our findings indicate that some commercial methods can be useful for fluconazole susceptibility testing of clinical Candida isolates. Those characterized by a lack of medium standardization and/or objective interpretative criteria should be avoided. Particular caution is necessary when testing is being done for clinical and epidemiological purposes.
采用美国国家临床实验室标准委员会(NCCLS)M27 - A方法(金标准)以及六种商业产品(Candifast、纸片法、Etest、Fungitest、Integral System Yeasts和Sensititre YeastOne),对800株临床念珠菌分离株(60%为白色念珠菌)和两株对照菌株(克鲁斯念珠菌ATCC 6258和近平滑念珠菌ATCC 22019)进行氟康唑敏感性测试。根据M27 - A标准,或者对于Fungitest、Integral System Yeasts和Candifast,按照制造商的说明,将结果分类为敏感、剂量依赖性敏感或耐药,分别对应敏感、中介或耐药。采用卡方检验分析与NCCLS M27 - A结果的一致性。同时评估了实验室内和实验室间的重复性。NCCLS M27 - A(90.1%)、Etest(93.1%)、Sensititre YeastOne(93.1%)、纸片法(96.7%)、Fungitest(92.6%)、Integral System Yeasts(40.6%)和Candifast(6.0%)将所示百分比的白色念珠菌分离株分类为敏感。在非白色念珠菌菌株中,敏感分离株的百分比分别如下:NCCLS M27 - A为74.0%;Etest为83.8%;Sensititre YeastOne为64.1%;纸片法为60.6%;Fungitest为76.6%;Integral System Yeasts为28.3%;Candifast为27.4%。除Candifast和Integral System Yeasts外,所有方法对白色念珠菌和非白色念珠菌分离株与NCCLS M27 - A结果均显示出良好的一致性。NCCLS M27 - A、Etest、Sensititre YeastOne、纸片法和Fungitest的实验室内重复性极佳(88%至91%)。实验室间重复性评估也得出了类似结果。我们的研究结果表明,一些商业方法可用于临床念珠菌分离株的氟康唑敏感性测试。应避免使用那些缺乏培养基标准化和/或客观解释标准的方法。在进行临床和流行病学检测时,尤其需要谨慎。